title: Beyond genomics.
abstract: The sequencing of the human genome has already had an enormous impact on medicine, particularly with single-gene changes that predispose to a serious disease such as cystic fibrosis or the overexpression of Her2 in about one-third of breast cancers. Genetic technology has led to some very important therapeutic innovations, including the use of imatinib mesylate (Gleevec) in BCR-ABL chronic myeloid leukemia and of trastuzumab (Herceptin) in Her2-positive breast cancer, but the much anticipated explosion of new effective treatments has been more modest than expected.
authors.affiliation: GlaxoSmithKline, Harlow, UK. colin.dollery@gsk.com
authors.forename: C T
authors.initials: CT
authors.lastname: Dollery
mesh_terms: D000818:Animals; D035843:Biomedical Research / Q000639:trends; D002986:Clinical Trials as Topic / Q000639:trends; D015195:Drug Design; D004345:Drug Industry / Q000639:trends*; D015894:Genome, Human; D023281:Genomics; D006801:Humans; D018579:Patient Selection; D010597:Pharmacogenetics / Q000639:trends*; D010601:Pharmacology, Clinical / Q000639:trends*; D010829:Physiological Phenomena / Q000187:drug effects* / Q000235:genetics; D010827:Physiology / Q000639:trends*; D012107:Research Design / Q000639:trends; D049490:Systems Biology / Q000639:trends; D000078329:Workforce